Interactions between Fostamatinib and Ondansetron

Ondansetron has a major potential interaction with Arrhythmia.

ECG changes including QT interval prolongation have been observed in patients receiving ondansetron. Additionally, there have been some postmarketing reports of Torsade de Pointes cases. The use of ondansetron should be avoided in patients with congenital long QT syndrome. ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.

Fostamatinib has a moderate potential interaction with Diarrhea.

The use of fostamatinib may cause diarrhea. Monitor patients for the development of diarrhea during treatment with fostamatinib. It is recommended to manage diarrhea using supportive care measures, including dietary changes, hydration and/or antidiarrheal medication, early after the onset of symptoms. Interrupt, dose reduce, or discontinue treatment if diarrhea becomes severe (Grade 3 or above). Care should be exercised when using this agent in patients with diarrhea.

Ondansetron has a major potential interaction with Heart Failure.

ECG changes including QT interval prolongation have been observed in patients receiving ondansetron. Additionally, there have been some postmarketing reports of Torsade de Pointes cases. The use of ondansetron should be avoided in patients with congenital long QT syndrome. ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.

Fostamatinib has a moderate potential interaction with High Blood Pressure.

The use of fostamatinib may cause hypertension. It is recommended to monitor blood pressure every 2 weeks until stable, then monthly and to adjust or initiate antihypertensive therapy to ensure maintenance of blood pressure control during treatment. If increased blood pressure persists despite appropriate therapy, therapy interruption, reduction or discontinuation may be necessary. Caution should be exercised when using this agent in patients with pre-existing hypertension as they may be more susceptible to the hypertensive effects of fostamatinib.

Ondansetron has a major potential interaction with Hypokalemia.

ECG changes including QT interval prolongation have been observed in patients receiving ondansetron. Additionally, there have been some postmarketing reports of Torsade de Pointes cases. The use of ondansetron should be avoided in patients with congenital long QT syndrome. ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.

Fostamatinib has a moderate potential interaction with Liver Disease.

The use of fostamatinib may result in elevated liver function tests, mainly ALT and AST. It is recommended to monitor liver function tests monthly during treatment. Treatment with fostamatinib should be interrupted, reduced, or discontinued if ALT or AST increase more than 3 × ULN. Use care using this agent in patients with liver problems.

Ondansetron has a moderate potential interaction with Liver Disease.

Ondansetron is extensively metabolized by the liver. The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function. During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported. Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease. The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.

Ondansetron has a major potential interaction with Magnesium Imbalance.

ECG changes including QT interval prolongation have been observed in patients receiving ondansetron. Additionally, there have been some postmarketing reports of Torsade de Pointes cases. The use of ondansetron should be avoided in patients with congenital long QT syndrome. ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.

Fostamatinib has a moderate potential interaction with Neutropenia.

Neutropenia has been reported in patients treated with fostamatinib. It is recommended to monitor the ANC monthly, and for infection during treatment and manage toxicity with treatment interruption, reduction or discontinuation.